Sees Q2 adjusted EBITDA $45M-$50M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- MCOs’ ‘mixed messages’ creating volatility in value-based care, says Truist
- Astrana Health initiated with an Equal Weight at Barclays
- Astrana Health Appoints New Chief Accounting Officer
- Astrana Health price target lowered to $46 from $50 at Truist
- Astrana Health Highlights Strategic Acquisition Plans